This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NVUS Novus Therapeutics (NVUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrendsBuy This Stock About Novus Therapeutics Stock (NASDAQ:NVUS) 30 days 90 days 365 days Advanced Chart Get Novus Therapeutics alerts:Sign Up Key Stats Today's Range$2.41▼$2.5550-Day Range$9.85▼$16.5052-Week Range$4.50▼$27.32Volume677,566 shsAverage Volume78,851 shsMarket Capitalization$3.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California. Read More Receive NVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVUS Stock News HeadlinesPtc Therapeutics Share Price (PTCT.US)November 5, 2024 | lse.co.ukCAMP4 Therapeutics Corp.October 23, 2024 | money.usnews.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)Tango Therapeutics Share Price (TNGX.US)September 3, 2024 | lse.co.ukSarepta Therapeutics Share Price (SRPT.US)July 21, 2024 | lse.co.ukVivoryon Therapeutics NV VVYMarch 1, 2024 | morningstar.comMViking Therapeutics IncFebruary 22, 2024 | money.usnews.comCYT Cyteir Therapeutics, Inc.December 28, 2023 | seekingalpha.comSee More Headlines NVUS Stock Analysis - Frequently Asked Questions How were Novus Therapeutics' earnings last quarter? Novus Therapeutics, Inc. (NASDAQ:NVUS) announced its quarterly earnings data on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing analysts' consensus estimates of ($1.64) by $3.87. When did Novus Therapeutics' stock split? Novus Therapeutics's stock reverse split before market open on Monday, October 5th 2020.The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Novus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novus Therapeutics investors own include SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), Bristol Myers Squibb (BMY), Miragen Therapeutics (MGEN), Selecta Biosciences (SELB) and Tonix Pharmaceuticals (TNXP). Company Calendar Last Earnings11/16/2020Today9/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NVUS CIK1404281 Webnovustherapeutics.com Phone949-238-8090FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-133.49% Return on Assets-30.52% Debt Debt-to-Equity RatioN/A Current Ratio18.78 Quick Ratio18.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.13 per share Price / Book0.18Miscellaneous Outstanding Shares1,436,000Free FloatN/AMarket Cap$3.48 million OptionableNot Optionable Beta2.07 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NVUS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.